'Life-saving' kidney cancer drug rejected over high costs

A drug which offers fresh hope to patients with deadly kidney cancer was rejected by NHS advisers yesterday.

Health boards in Scotland have been told not to fund the treatment Sutent because it fails the cost-effectiveness test.